412 related articles for article (PubMed ID: 24016069)
1. Pimavanserin for the treatment of Parkinson's disease psychosis.
Friedman JH
Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
[TBL] [Abstract][Full Text] [Related]
2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
3. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
[No Abstract] [Full Text] [Related]
4. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
5. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin for the treatment of Parkinson's disease psychosis.
Chendo I; Ferreira JJ
Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin.
Hunter NS; Anderson KC; Cox A
Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
9. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
12. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K; Price DL; Bonhaus DW
Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Stahl SM
CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
[TBL] [Abstract][Full Text] [Related]
14. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
[TBL] [Abstract][Full Text] [Related]
15. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
16. Pimavanserin as treatment for Parkinson's disease psychosis.
Fox SH
Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
[No Abstract] [Full Text] [Related]
17. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions for psychosis in Parkinson's disease patients.
Friedman JH
Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
[TBL] [Abstract][Full Text] [Related]
19. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Panchal SC; Ondo WG
Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin: First Global Approval.
Markham A
Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]